PubMed Health⌕ Search

Biomedical subjects

M D Culler

Publications and source records attributed to M D Culler.

At least 73 records · Page 4Linked to original sources
PubMed1987

Immunocytochemical localization of inhibin in rat and human reproductive tissues.

Recently, the structures of two forms of inhibin present in human follicular fluid were elucidated from the corresponding cDNA sequences. Using specific antisera generated against the alpha-chain common to both forms, we have examined the cellular localization of inhibin in the male and female rat gonads and in human placental tissue. Specific alpha-inhibin immunoreactivity was localized within the Sertoli cells of a number of tubules in each testes section. However, other adjacent tubules were unstained suggesting a stage-specific production of inhibin. Intense immunostaining was observed in the granulosa cells of ovarian follicles at various stages but not in the thecal cells. Immunostaining was present in the human placenta and limited to the cytotrophoblast cells, suggesting a role of inhibin during pregnancy. The present study demonstrates the probable site of production of inhibin in the gonads and placenta and further implicates this important factor as a key regulator of reproductive functions.

Animals↗
PubMed1987

Immunocytochemical localization of the gonadotropin-releasing hormone-associated peptide of the LHRH precursor.

Using specific rabbit anti-GAP (gonadotropin-releasing hormone-associated peptide) serum, we have immunocytochemically localized GAP in the rat brain. Immunostaining of neuronal perikarya, fibers and terminals was demonstrated with GAP antiserum under conditions of tissue preparation which make immunostaining with LHRH antisera difficult or undetectable. GAP-immunoreactive perikarya were observed in sections of perfused or nonperfused brains without colchicine pretreatment. Using a double immunoperoxidase staining method, both GAP and LHRH immunoreactivities were shown to coexist in the same neurons. The common distribution of LHRH and GAP immunoreactivity in the rat brain is strongly supportive of GAP representing the non-LHRH portion of the LHRH precursor. The use of GAP antisera that can distinguish between LHRH and the remaining portion of its prohormone represents a valuable tool for studies of LHRH-prohormone processing and distribution.

Animals↗
PubMed1987

Pulsatile follicle-stimulating hormone secretion is independent of luteinizing hormone-releasing hormone (LHRH): pulsatile replacement of LHRH bioactivity in LHRH-immunoneutralized rats.

We recently reported that passive immunoneutralization of endogenous LHRH in castrate male rats completely abolishes pulsatile LH secretion and, within 1 h, lowers mean plasma LH by 86%. While pulsatile FSH secretion, in terms of pulse amplitude and frequency, is not affected, mean plasma FSH is gradually lowered but only by 49% after 24 h. In the present study, we have examined the effect of replacing pulsatile LHRH biological activity on LH and FSH secretion in 4-week castrate male rats in which endogenous LHRH has been immunoneutralized by ovine anti-LHRH serum 772 (LHRH-AS) for 24 h. The LHRH-AS requires the 3-10 amino acid sequence of LHRH including the amidated C terminus for complete recognition. In order to circumvent the antiserum blockade, we utilized the LHRH agonist [Des Gly10]-LHRH ethyl amide (DG-LHRH) which is minimally recognized by the LHRH-AS but which possesses 2.6-fold the LH-releasing activity of LHRH. Twenty-four hours after injecting 500 microliter LHRH-AS into cannulated, castrate rats, sequential blood samples were taken every 10 min for 4 h. Bolus 3-ng injections of either DG-LHRH or saline were given iv either every 30 min during the 4-h collection period or every 30 or 60 min for 10 h before the initiation of and continuing through the 4-h collection period. Each DG-LHRH injection stimulated the release of a single pulse of LH, while pulsatile FSH secretion was unaffected. No synchrony was observed between the DG-LHRH pulses and the endogenous FSH pulses. Short term DG-LHRH treatment partially restored, and long term DG-LHRH treatment every 60 min completely restored, mean plasma FSH to the level observed in nonantiserum-treated castrate control rats. Long term DG-LHRH treatment every 30 min caused a rise in mean plasma FSH which exceeded the plasma FSH level of the nonantiserum-treated controls. The mean plasma level of LH was entirely dependent on the frequency of the DG-LHRH injection. The results of this study clearly demonstrate that pulsatile FSH secretion is independent of LHRH but that LHRH is required to elevate and/or maintain high mean plasma FSH levels. Trough levels of LH, however, are dependent on the frequency of LHRH-induced pulsatile LH secretion.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗
PubMed1987

Pulsatile peptide secretion: encoding of brain messages regulating endocrine and reproductive functions.

Neuropeptides are defined chemical messengers produced by the brain to modulate its own activity and also to regulate the function of every organ system. These neuropeptides can be viewed as coded chemical signals produced by the brain and secreted into the blood or into other fluids, such as the cerebrospinal fluid, to be transported and to act at a distant site. The signals arrive to the target organ or sometimes to an intermediary station, such as the pituitary gland, where they are decoded, transformed into a more powerful signal, and sent again through the general circulation to reach their final target. Our work has characterized the episodic or pulsatile pattern of secretion of a number of peptide hormones produced by the brain or the pituitary gland and analyzed the brain mechanisms involved in the generation of such a pulsatile pattern of hormone secretion. Molecular biology approaches have provided information on the synthesis, processing, and secretion of these brain messengers. In addition, using computer-assisted perifusion systems, we have been able to reproduce in vitro some of the signals produced by the brain and are currently trying to decode the message carried by those signals, as well as determining the intracellular messengers involved in the signal process. The importance of the neuropeptides and of the messages carried by the pulsatile signal is underlined by experiments in which animals treated with a neurotoxin were rendered infertile.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1986

Peptide-steroid interactions in brain regulation of pulsatile gonadotropin secretion.

Reproductive function is regulated by an intricate system of peptide, steroid and amine factors interacting within the brain, pituitary and gonads. At no point is the complexity of the reproductive system better exemplified than in the exquisite interplay of factors required to produce and modulate pulsatile gonadotropin secretion. By extension, analysis of the pulsatile secretory pattern of the gonadotropins, as a means of assessing the contribution of these various factors, can reveal interactions too subtle to be detected by the conventional examination of mean gonadotropin concentration. Analysis of the pulsatile secretory patterns of both LH and FSH reveals striking differences between the two gonadotropins in their response to inhibitory, gonadal peptide and steroid factors, suggesting divergent paths of brain-pituitary regulation. Further studies to clarify this disparity in regulation have demonstrated that neutralization of endogenous LHRH completely abolishes pulsatile LH secretion without affecting pulsatile FSH secretion, suggesting the existence of another, as of yet unknown, brain factor which regulates FSH secretion. The feedback signals provided by gonadal steroids can induce both inhibition and facilitation of LHRH and LH secretion. Neurons of the central opiatergic system exert a tonic inhibitory influence on the catecholaminergic neurons regulating LHRH secretion, and are believed to mediate the inhibitory actions of the gonadal steroids on the LHRH system. Withdrawal of the gonadal steroids has been reported to cause a rapid loss of the tonic inhibitory control of the opiate system on LHRH secretion as revealed by a lack of response to naloxone. Reassessment of this system by analyzing the pulsatile pattern of LH secretion, however, reveals that the loss of naloxone effect after gonadectomy occurs very gradually and that an effect can still be obtained up to 2 weeks after the removal of gonadal steroids. These studies provide excellent examples of the complex interplay observed just between selected factors regulating pulsatile gonadotropin secretion. The use of pulsatile gonadotropin analysis is a powerful model, not only for providing greater clarity of known regulatory interactions, but also for revealing new and more subtle levels of control in the brain-pituitary-axis.

Animals↗
PubMed1986

Development of specific antisera and a radioimmunoassay procedure for the gonadotropin-releasing hormone associated peptide (GAP) of the LHRH prohormone.

Recently, the structure of the cDNAs encoding the human and rat LHRH prohormones were determined and the corresponding peptide sequences deduced. In addition to LHRH, both cDNAs encoded a 56 amino acid sequence which has been designated gonadotropin-releasing hormone associated peptide (GAP). In order to initiate studies on the LHRH prohormone, three antisera (MC-1, MC-2 and MC-3) were generated using the human GAP (hGAP) 25-53 fragment as immunogen and a corresponding radioimmunoassay procedure was developed. The binding of 125I-labeled hGAP 1-56 to all three antisera was displaced completely by unlabeled hGAP 1-56. Acid extracts of rat median eminence produced displacement curves that were parallel to the hGAP 1-56 curve. Conversely, extracts of rat cortex and a number of brain and pituitary peptides, including LHRH and LHRH analogs, did not affect tracer binding. Several fragments of the human and rat GAP (rGAP) sequences (hGAP 25-53, hGAP 27-40 and rGAP 20-43) produced tracer displacement curves that were non-parallel with the hGAP 1-56 curve and/or gave only incomplete tracer displacement when all three antisera were tested. This suggests that the antisera contain multiple antibody populations directed toward several different antigenic determinants within the mid portion of the hGAP and rGAP sequences. The rGAP fragments, rGAP 1-11 and rGAP 39-53, failed to displace the tracer, further supporting that the antigenic sites occur within the mid portion of the rGAP sequence.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1986

Evidence that pulsatile follicle-stimulating hormone secretion is independent of endogenous luteinizing hormone-releasing hormone.

Although LHRH can stimulate the release of both LH and FSH from the pituitary, there are a number of instances in which the secretion of LH and FSH are divergent. Previous studies from our laboratory have indicated that pulsatile LH and FSH secretion are independently regulated by gonadal factors. We have, therefore, reexamined the role of LHRH in regulating pulsatile gonadotropin secretion by evaluating the effect of passive LHRH immunoneutralization on LH and FSH secretion in castrate adult male rats. Injection of 500 microliters ovine anti-LHRH serum no. 772 (LHRH-AS) into 2-week-castrate rats caused an 85% suppression of mean plasma LH levels by 2 h, which lasted through 48 h. Mean plasma FSH, however, was reduced by only 19% after 2 h and by only 59% after 48 h. When cannulated 2-week-castrate rats were bled every 10 min, both LH and FSH were secreted in a pulsatile manner. Injection of 500 microliters LHRH-AS caused an immediate abolishment of LH pulses and a rapid reduction in mean plasma LH through 24 h. Pulsatile FSH secretion, as characterized by the parameters of pulse frequency and amplitude, was unaffected by LHRH-AS, although mean plasma FSH levels were significantly reduced. Collectively, the results suggest that pulsatile FSH secretion is regulated by a separate factor(s) distinct from LHRH, but that LHRH is required for the maintenance of elevated FSH levels.

Animals↗
PubMed1986

Angiotensin II-like immunoreactivity in human ovarian follicular fluid.

Human ovarian follicular fluid (hFF) has angiogenic activity, although the causative factors are unknown. We recently found that hFF contains renin activity which converts renin substrate to angiotensin I (AI). Since the enzymatic cleavage product of AI, angiotensin II (AII), is a potent stimulator of new vessel formation, we have examined Sephadex G-25 column fractions of hFF and extracted hFF and plasma from individual patients for AII-like immunoreactivity (AII-IR). Eluent fractions from Sephadex G-25 column chromatography of hFF had significant AII-IR which eluted in the same fractions as synthetic AII. Individual, extracted FF samples contained approximately 10 times higher levels of AII-IR than extracts of plasma from the same patients. Serial dilutions of the Sephadex column fractions and extracted FF and plasma inhibited binding of 125I-AII to rabbit anti-AII serum in a manner parallel to the inhibition caused by synthetic AII, indicating that the detected immunoreactivity was not due to non-specific assay interference. In summary, the results indicate the presence of significant AII-like immunoreactivity in hFF. AII may now be considered as a potential mediator of the angiogenic activity present in hFF and may play an important paracrine and/or autocrine role in physiologic events in the ovary.

Angiotensin II↗
PubMed1984

Growth hormone releasing factors in the brain and the gut: chemistry, actions, and localization.

Within the physiological range of other known releasing factors, human pancreatic tumor growth hormone releasing factor (hpGRF) is specific for GH release. Data concerning hpGRF action on cAMP and GH are consistent with the concept of cAMP acting as a second messenger for this releasing factor. hpGRF-stimulated GH release is Ca++ dependent. Exogenous hpGRF40 does not alter the interdigestive gastric motility or secretion of gastrin and motilin in dogs, while large doses of hpGRF stimulate somatostatin release into the hepatic portal blood of the rat. Significant GRF activity as determined by a rat pituitary perifusion system is confined within the median eminence and the arcuate nucleus, though detectable but insignificant GRF activity is present in other area of the hypothalamus and cortex in the rat. GRF activity is present in the ovine brain as well as in the gut. Both tissues contain large (between 4000-5000 daltons) and small (but possibly larger than 1000 daltons) m.w. GRF materials. GRF appears to be structurally different between species and more than one GRF may be present within the same species. One of the ovine brain peptides with GH-releasing activity was partially characterized as His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr- Lys-Arg-Try-Asn-Lys-Glu-Met- Ala-Lys--which is similar to rat GRF and porcine VIP having His at the N-terminus. Another peptide with GRF activity which eluted earlier on reverse phase HPLC and later on cation exchange chromatography has also been obtained in a pure form.(ABSTRACT TRUNCATED AT 250 WORDS)

1-Methyl-3-isobutylxanthine↗
PubMed1984

Stimulation of pituitary cAMP accumulation by human pancreatic GH-releasing factor-(1-44).

This study seeks to determine whether hpGRF-(1-44) stimulates pituitary growth hormone (GH) secretion and cAMP accumulation in a manner that is consistent with the concept of cAMP as an intracellular mediator of GH release. Addition of 10 nM hpGRF-(1-44) to rat anterior pituitary cell cultures stimulated a rapid elevation of intracellular cAMP that preceded or coincided with increases in GH and cAMP secretion. A dose-related increase in GH and cAMP release and in intracellular cAMP accumulation was observed in response to increasing concentrations of hpGRF-(1-44). Stimulation of cAMP accumulation and release, however, occurred over a hpGRF-(1-44) concentration range that was approximately one order of magnitude higher than required for dose-related GH release. Simultaneous addition of 0.05 nM hpGRF-(1-44) and 0.2, 0.5, or 1.0 mM 3-isobutyl-1-methylxanthine (MIX) to the cultures resulted in a significant potentiation of intracellular cAMP accumulation and release. Potentiation of GH release was not observed, however, probably due to attainment of maximal or near maximal GH release by MIX alone. The addition of increasing doses of exogenous N6-O2'-dibutyryladenosine 3',5'-cyclic monophosphate (DBcAMP) to cell cultures resulted in a dose-related increase in GH secretion. The results of this study are consistent with the concept of cAMP as a second messenger for hpGRF-(1-44) in stimulating GH release. Additionally, a novel method for cAMP extraction that utilizes trifluoroacetic acid is described.

1-Methyl-3-isobutylxanthine↗
PubMed1983

Effects of ethanol on rat hypothalamic luteinizing hormone releasing hormone. A study utilizing radioimmunoassay.

To further understand the mechanism of action by which ethanol (ETOH) decreases plasma luteinizing hormone (LH) levels, the effects of multiple i.p. injections of EOH (1.0--1.5 g/kg) or saline on hypothalamic luteinizing hormone releasing hormone (LHRH) and plasma LH concentrations were evaluated in intact and castrate male rats. After injections, animals were decapitated, brains rapidly removed, and blocks containing the hypothalamus [with median eminence (ME)] were isolated. Hypothalami were subjected to acetic acid extraction and LHRH content quantitated via radioimmunoassay (RIA). Hypothalamic LHRH was found to be inversely correlated with plasma LH. In response to castration, both saline and ETOH-treated rats showed a decrease in hypothalamic LHRH content with a concomitant increase in plasma LH; however, the ETOH-treated animals retained significantly greater concentrations of LHRH and showed significantly lower plasma LH levels when compared to saline-treated controls. Likewise, ETOH-treated intact animals showed significant increases in LHRH content, with LH levels remaining significantly lower than the saline-treated intact controls. Thus, these data from both intact and castrate rats provide evidence to support the hypothesis that alcohol-induced decreases in LH levels are due to a diminished release rate of hypothalamic LHRH.

Animals↗
PubMed1983

Arginine8 vasopressin potentiates the beta-endorphin-releasing activity of ovine corticotropin-releasing factor (oCRF) in vitro.

The ability of arginine8 vasopressin (AVP) to potentiate the beta-endorphin-releasing activity of synthetic ovine corticotropin releasing factor (oCRF) was examined using an anterior-pituitary quarter assay. Both AVP and oCRF stimulated the release of beta-endorphin immunoreactivity (beta-END-I) in a dose-dependent manner, with AVP being approximately 10 times less effective than oCRF. Marked potentiation of beta-END-I release was observed when pituitary quarters were incubated in the presence of a combination of 0.5 nM oCRF and 1.0 nM AVP. Further potentiation was not observed when the higher doses of 1.0 nM oCRF and 2.0 nM AVP were tested in combination; however, maximal beta-END-I release may have been attained by the addition of 1.0 nM oCRF alone. These results suggest that AVP may play a role in the mediation of beta-endorphin release from the adenohypophysis.

Animals↗
PubMed1982

Inhibition of the postovariectomy depletion of hypothalamic luteinizing hormone releasing hormone (LHRH) by suckling.

A study was undertaken to further the understanding of the mechanism by which suckling inhibits the release of pituitary LH and depresses the postovariectomy rise of plasma LH in lactating mammals. To that end, the effect of suckling (10 pups/animal) for 1 or 3 weeks on the LHRH content of the hypothalamus and preoptic area (POA) in ovariectomized and intact rats was examined. Controls consisted of intact and 1 or 3 week ovariectomized, nonlactating animals. Following decapitation, the brains were rapidly removed and blocks containing the POA and the hypothalamus (with median eminence) were isolated. Tissue was extracted with acetic acid and LHRH quantitated via validated RIAs utilizing 2 antisera specific for different portions of the LHRH molecule. Ovariectomy of nonlactating, diestrous animals resulted in a significant decline in hypothalamic LHRH, reaching 50% of control levels by 3 weeks. During the same intervals, plasma LH increased dramatically to 20- and 60-fold over intact controls by 1 and 3 weeks, respectively. In contrast, LHRH levels were not decreased at 1 or 3 weeks in ovariectomized rats which were suckled, at which time plasma LH was greatly depressed. When intact animals were evaluated, the suckling stimulus failed to induce a detectable change in LHRH content of the hypothalamus of LHRH in the POA between any of the treatment or control groups. These data from ovariectomized rats suggest that suckling inhibits LHRH release from the hypothalamus and hence provides an explanation for the depression of plasma LH observed in suckled ovariectomized and intact animals.

Animals↗
PubMed1982

Immunocytochemical evidence that suckling inhibits the postovariectomy depletion of median eminence luteinizing hormone releasing hormone.

Suckling has been demonstrated to impair the release of pituitary luteinizing hormone (LH) and to prevent the dramatic increase in plasma LH observed following ovariectomy. In the present study, the effect of suckling (10 pups/animal) for either 1 or 3 weeks on the relative amount of luteinizing hormone releasing hormone (LHRH) present in the hypothalamus and preoptic area of ovariectomized and intact rats was examined using immunocytochemical methodology. Controls consisted of nonlactating animals which were either intact (diestrous) or ovariectomized for 1 or 3 weeks. Brains were removed following transcardial perfusion of phosphate-buffered formalin and Bouin's fixative. After dehydration, clearing and paraffin embedding, the brains were sectioned and LHRH localized by an indirect immunoperoxidase technique. A positive reaction denoting the presence of immunoreactive LHRH was observed over axons and termini throughout the rostral to caudal extent of the median eminence (ME) and surrounding the organum vasculosum of the lamina terminalis (OVLT) in the preoptic area. Ovariectomy resulted in a progressive decline in the concentration of LHRH within the ME as evidenced by a reduction in the intensity of the staining reaction and in the number of axons over which the reaction was observed. In contrast, brains from ovariectomized rats which had been suckled appeared to have concentrations of LHRH in the ME equal to or greater than that of the diestrous controls. Similarly, the concentrations of LHRH In the ME of intact, suckled rats did not differ significantly from that of the diestrous controls. Neither ovariectomy nor suckling produced any observable change in the relative concentration of LHRH located near the OVLT. These data demonstrate that suckling prevents the depletion of LHRH from the ME following ovariectomy and provide evidence for mechanism by which the suckling stimulus may suppress plasma LH.

Animal Population Groups↗
PubMed1981

In vivo and in vitro release of ACTH by synthetic CRF.

The 41-residue corticotropin releasing factor (CRF) was synthesized by the solid phase method. The synthetic CRF and arginine vasopressin (AVP) were examined for ACTH releasing activity and effects on the release of 5 other pituitary hormones in vivo and in vitro. Injection of the CRF into pharmacologically blocked rats increased plasma corticosterone levels in a dose-related manner. The minimum effective dose was 1.6 x 10(-12) mol/100 g body weight. CRF also significantly stimulated release of ACTH-like immunoreactivity in a dose-related manner from rat pituitary quarters beginning at a concentration of 10(-9) M. AVP, a peptide known to have CRF activity, exhibited slightly lower corticotropin releasing activity than the CRF at equimolar dose levels. Secretion of other pituitary hormones was not appreciably altered by either the CRF or AVP.

Adrenocorticotropic Hormone↗
PubMed1980

Mastitis: II. Evaluation of antimicrobial amines for use as teat dips.

Recent proposals by the Food and Drug Administration to regulate teat dips as drugs have led to a search for safer teat dip ingredients. Primary, secondary, and tertiary alkyl amines (carbon-10 to -18 chain length) inhibit growth of mastitic bacteria (Streptococcus agalactiae, Streptococcus uberis, Staphylococcus aureus, Escherichi coli, Klebsiella pneumoniae) in a broth tube culture assay. Since carbon-13 compounds were active, a carbon-13 primary (tridecanamine hydrochloride), secondary methyl (N-methyltridecanamine), secondary ethyl (N-ethyltridecanamine), tertiary dimethyl amine (N, N-dimethyltridecanamine), and carbon-12 quaternary amine (N, N, -trimethyldodecaneammonium chloride) were tested for their ability to reduce experimentally applied populations of S. agalactiae or E. coli on the bovine teat surface. The five compounds were compared at concentrations of 100, 500, 1,000, 3,000, 7,000, and 10,000 ppm. Activity was greater against the gram-positive S. agalactiae than against the gram-negative E. coli. The tertiary amine was most active, producing a log reduction of 4 (reduction of bacterial number from 10(6) to 10(2)) at a concentration of 3,000 ppm in the teat dip. The relative order of effectiveness for the amines was: dimethyl tertiary greater than methyl secondary greater than ethyl secondary greater than primary = quaternary. The results suggest that these amines may be useful as potent, effective antibacterial agents for incorporation into teat dips.

Amines↗
PubMed1979

Mastitis: I. In vitro antimicrobial activity of alkyl amines against mastitic bacteria.

The activities of branched and straight chain amines (10 to 18 carbons chain length) were compared in inhibiting the growth of five microorganisms that cause about 95% of bovine mastitis. Three gram-positive (Streptococcus agalactiae, Streptococcus uberis, Staphylococcus aureus) and two gram-negative (Escherichia coli, Klebsiella pneumoniae) bacteria were used in a trypticase soy broth tube culture growth assay. Sixty-two compounds were screened at concentrations of 200, 100, 50, 25, 10, 5, and 1 ppm in broth culture to determine the effective minimum inhibitory concentration. Alkyl secondary N-substituted monoethyl [CH3(CH2)nNHCH2CH3] and tertiary N,N-substituted dimethyl [CH3(CH2) nN(CH3)2] amines with chain lengths of 11 to 14 carbon atoms were active against both gram-positive and gram-negative organisms. Antimicrobial activity against gram-positive organisms increased with increasing chain length and carbon-14 to 18 amines were active at 1 to 5 ppm. The carbon-11 to 13 alkyl amines were most active against gram-positive organisms; longer chain amines (more than 14 carbons) were inactive. Branching of the alkyl chain caused a loss of activity against gram-negative but not against gram-positive bacteria. Antimicrobial testing of monoamines, polyamines, and the influence of order substituents were investigated to correlate structure-acitivity relationships.

Amines↗